|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...132133134135136137138139140141142...156157» |
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Observational data, Enrollment change, Adverse events, Serious adverse event: The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=35, Completed, Sponsor: University Hospital, Toulouse
N=50 --> 35
- Enrollment change: Coping Skills Training for Early Rheumatoid Arthritis (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=105, Completed, Sponsor: Duke University
N=50 --> 35 N=225 --> 105
- ||||| mavrilimumab (KPL-301) / Kiniksa
New P2 trial: A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 21, 2012
P2, N=400, Recruiting, Sponsor: MedImmune LLC
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial, PK/PD data: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety (clinicaltrials.gov) - Oct 21, 2012
P2, N=100, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | New P2 trial: Ginseng in Treatment of Fatigue in Multiple Sclerosis (clinicaltrials.gov) - Oct 21, 2012
P2, N=60, Completed, Sponsor: Isfahan University of Medical Sciences
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Observational data, Adverse events, Serious adverse event: The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders (clinicaltrials.gov) - Oct 21, 2012
P=N/A, N=35, Completed, Sponsor: University Hospital, Toulouse
N=225 --> 105 Recruiting --> Completed
- ||||| Smyraf (peficitinib) / Astellas, Maruho
New P2 trial, P2 data: A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study (clinicaltrials.gov) - Oct 18, 2012
P2, N=611, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- Enrollment open: PRISM: Pictorial Representation of Illness and Self Measure (clinicaltrials.gov) - Oct 18, 2012
P=N/A, N=0, Recruiting, Sponsor: University of Oxford
Recruiting --> Completed Not yet recruiting --> Recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 (clinicaltrials.gov) - Oct 18, 2012
P=N/A, N=125, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Enrollment closed: Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions (clinicaltrials.gov) - Oct 17, 2012
P3, N=201, Active, not recruiting, Sponsor: BioMimetic Therapeutics
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: A Nutritional Intervention for Arthritis (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=32, Completed, Sponsor: Physicians Committee for Responsible Medicine
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Enrollment open: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Oct 17, 2012
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- New P4 trial: Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (clinicaltrials.gov) - Oct 16, 2012
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
- | New P2 trial: Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 16, 2012
P2, N=78, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||| mavrilimumab (KPL-301) / Kiniksa
Trial completion: A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 16, 2012
P2, N=291, Completed, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P3 trial: To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) (clinicaltrials.gov) - Oct 16, 2012
P3, N=522, Recruiting, Sponsor: Sanofi
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P3 trial: PREDICTIVE (clinicaltrials.gov) - Oct 16, 2012
P3, N=2287, Completed, Sponsor: Novo Nordisk
- |||||||||| New P3 trial: Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Oct 14, 2012
P3, N=753, Completed, Sponsor: Novo Nordisk
- | Symlin (pramlintide) / AstraZeneca
New P1 trial: Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM (clinicaltrials.gov) - Oct 14, 2012
P1, N=20, Recruiting, Sponsor: Amylin Pharmaceuticals, LLC.
- ||| Betaseron (IFN-β-1b) / Bayer
Clinical: Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=650, Recruiting, Sponsor: Bayer
- leflunomide / Generic mfg.
Trial initiation date, Head-to-Head: Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=15, Completed, Sponsor: Chinese Academy of Sciences
Recruiting --> Completed Initiation date: Jun 2012 --> Oct 2012
- || Enrollment change: DAWN2: Diabetes Attitudes Wishes and Needs (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=8985, Completed, Sponsor: Novo Nordisk
Initiation date: Jun 2012 --> Oct 2012 N=16200 --> 8985
- Nulojix (belatacept) / BMS
Enrollment change: LEEP: LEA29Y (Belatacept) Emory Edmonton Protocol (clinicaltrials.gov) - Oct 11, 2012
P2, N=10, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=16200 --> 8985 N=20 --> 10
- ||| Tysabri (natalizumab) / Biogen
Clinical: COSTAN: Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=150, Recruiting, Sponsor: Biogen Idec
- ||||| mavrilimumab (KPL-301) / Kiniksa
New P2 trial: A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 11, 2012
P2, N=422, Completed, Sponsor: MedImmune LLC
- ||| Trial completion: DAWN2: Diabetes Attitudes Wishes and Needs (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=8985, Completed, Sponsor: Novo Nordisk
N=20 --> 10 Enrolling by invitation --> Completed
- ||| warfarin / Generic mfg.
Trial completion: Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=63, Completed, Sponsor: University of North Carolina, Chapel Hill
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Monotherapy: A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy (clinicaltrials.gov) - Oct 10, 2012
P=N/A, N=80, Recruiting, Sponsor: Hoffmann-La Roche
- Nucala (mepolizumab) / GSK
New P2 trial: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Oct 10, 2012
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - Oct 9, 2012
P=N/A, N=59, Completed, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Completed N=80 --> 59
- | Tresiba (insulin degludec) / Novo Nordisk
New P1 trial: A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine (clinicaltrials.gov) - Oct 9, 2012
P1, N=40, Completed, Sponsor: Novo Nordisk
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Oct 9, 2012
P4, N=17, Completed, Sponsor: Hoffmann-La Roche
N=80 --> 59 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment open: Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (clinicaltrials.gov) - Oct 8, 2012
P3, N=20, Recruiting, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Rebif (human IFN-β-1a) / EMD Serono
Trial completion: fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls (clinicaltrials.gov) - Oct 8, 2012
P4, N=21, Completed, Sponsor: Waukesha Memorial Hospital
Active, not recruiting --> Recruiting Recruiting --> Completed
- | Diamyd (recombinant 65 kDa isoform of human glutamic acid decarboxylase) / Diamyd Medical
Trial termination: A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT (clinicaltrials.gov) - Oct 8, 2012
P3, N=331, Terminated, Sponsor: Diamyd Therapeutics AB
Recruiting --> Completed Active, not recruiting --> Terminated; Based on other clinical trial results it was unlikely the study would meet the efficacy endpoints
- cyclophosphamide / Generic mfg.
Enrollment open, Adverse events: A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment (clinicaltrials.gov) - Oct 6, 2012
P=N/A, N=150, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Terminated; Based on other clinical trial results it was unlikely the study would meet the efficacy endpoints Not yet recruiting --> Recruiting
- | Plivensia (sirukumab) / J&J
New P1 trial: A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 4, 2012
P1, N=49, Completed, Sponsor: Centocor Research & Development, Inc.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial: Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE (clinicaltrials.gov) - Oct 3, 2012
P2, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Tysabri (natalizumab) / Biogen, Royalty, Betaseron (IFN-?-1b) / Bayer
New P4 trial: Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2012
P4, N=5, Terminated, Sponsor: Claudio Gobbi
- Enrollment open: WIRMS: Worms for Immune Regulation of Multiple Sclerosis (clinicaltrials.gov) - Oct 3, 2012
P2, N=72, Recruiting, Sponsor: University of Nottingham
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Cord Blood Plus Vitamin D and Omega 3s in T1D (clinicaltrials.gov) - Oct 3, 2012
P1, N=15, Completed, Sponsor: University of Florida
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Rebif (human IFN-β-1a) / EMD Serono
Enrollment open: EMR200136-549: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (clinicaltrials.gov) - Oct 1, 2012
P2, N=80, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial termination: DIAPASOM2: Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=79, Terminated, Sponsor: University Hospital, Grenoble
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; intermediary analysis was performed and significant results were found for the main objective
- Enrollment change: DIAPASOM2: Impact of Objective Sleep Duration on Blood Glucose Control in Type 1 Diabetes Adult Patients (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=79, Terminated, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Terminated; intermediary analysis was performed and significant results were found for the main objective N=140 --> 79
- Kineret (anakinra) / SOBI
Trial initiation date: Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes (clinicaltrials.gov) - Sep 30, 2012
P2, N=21, Recruiting, Sponsor: University of Colorado, Denver
N=140 --> 79 Initiation date: Nov 2011 --> Mar 2012
- Kineret (anakinra) / SOBI
Enrollment open: Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes (clinicaltrials.gov) - Sep 30, 2012
P2, N=21, Recruiting, Sponsor: University of Colorado, Denver
Initiation date: Nov 2011 --> Mar 2012 Not yet recruiting --> Recruiting
- Clinical: Outpatient Control-to-Range: System and Monitoring Testing (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=5, Active, not recruiting, Sponsor: Sansum Diabetes Research Institute
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P3 trial: Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes (clinicaltrials.gov) - Sep 30, 2012
P3, N=131, Completed, Sponsor: Novo Nordisk
- bortezomib / Generic mfg.
New P2 trial: CAD0111: Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease (clinicaltrials.gov) - Sep 27, 2012
P2, N=25, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
- Enrollment open: Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Sep 27, 2012
P4, N=188, Recruiting, Sponsor: University of Western Ontario, Canada
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting